Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Anfield Energy's updated PEA makes the Shootaring mill restart look explosive, but AEC is still a no-revenue uranium developer that has to clear permits, capital, reserves, construction, and first production.
OpenA filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenA source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenA CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
OpenA Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAdvanced Flower Capital's first quarter as a BDC showed dividend-covering NII and higher NAV, but three nonaccrual loans still represented 36.6% of amortized cost and 23.5% of fair value.
OpenAeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2
OpenAeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
OpenAENT is a profitable physical-media and collectibles distributor with more than $1 billion of annual revenue, improving margins, exclusive studio and label relationships, insider control and a balance sheet that depends on inventory, receivables and revolver a
OpenAEIS just put up 26% Q1 revenue growth, more than doubled Data Center Computing revenue, crossed a 40% non-GAAP gross-margin milestone, and priced $1.0 billion of 0% convertible notes. The upside is real; so are the customer, working-capital, and dilution ques
OpenAehr Test just printed a $37.2 million bookings quarter tied to AI processors, silicon photonics, and hyperscale data-center infrastructure. The harder part is still ahead: turning that order rebound into revenue, margin recovery, and per-share value after a w
OpenActivate Energy has no wells, no operating revenue, and no target yet. The source-backed story is a $230.6 million trust account, a December 2027 deal clock, oil-and-gas sponsor ambition, and a structure where Class A shares and warrants carry very different r
OpenAdvantage Solutions has national retail execution scale and positive adjusted EBITDA, but the equity case is hostage to Branded Services pressure, cash conversion, refinancing costs, and 4.2x net leverage.
OpenAduro has a real cash runway after two U.S. offerings, but the decision point is whether Hydrochemolytic Technology can move from customer trials and pilot work into demonstration-scale economics before burn and dilution absorb the runway.
OpenA filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenZymeworks Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZhengye Biotechnology Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Open